bluuebunny/crossref_metadata_2025_split huggingface dataset:
Simultaneous editing of three homoeologues of TaCIPK14 confers broad‐spectrum resistance to stripe rust in wheat
Authors: He Fuxin , Wang Ce , Sun Huilin , Tian Shuxin , Zhao Guosen , Liu Cong , Wan Cuiping , Guo Jia , Huang Xueling , Zhan Gangming , Yu Xiumei , Kang Zhensheng , Guo Jun 
Published: November 2022

SummaryWheat stripe rust caused by the fungus Puccinia striiformis f. sp. tritici (Pst) is one of the most destructive wheat diseases resulting in significant losses to wheat production worldwide. The development of disease‐resistant varieties is the most economical and effective measure to control diseases. Altering the susceptibility genes that promote pathogen compatibility via CRISPR/Cas9‐mediated gene editing technology has become a new strategy for developing disease‐resistant wheat varieties. Calcineurin B‐like protein (CBL)‐interacting protein kinases (CIPKs) has been demonstrated to be involved in defence responses during plant‐pathogen interactions. However, whether wheat CIPK functions as susceptibility factor is still unclear. Here, we isolated a CIPK homoeologue gene TaCIPK14 from wheat. Knockdown of TaCIPK14 significantly increased wheat resistance to Pst, whereas overexpression of TaCIPK14 resulted in enhanced wheat susceptibility to Pst by decreasing different aspects of the defence response, including accumulation of ROS and expression of pathogenesis‐relative genes. We generated wheat Tacipk14 mutant plants by simultaneous modification of the three homoeologues of wheat TaCIPK14 via CRISPR/Cas9 technology. The Tacipk14 mutant lines expressed race‐nonspecific (RNS) broad‐spectrum resistance (BSR) to Pst. Moreover, no significant difference was found in agronomic yield traits between Tacipk14 mutant plants and Fielder control plants under greenhouse and field conditions. These results demonstrate that TaCIPK14 acts as an important susceptibility factor in wheat response to Pst, and knockout of TaCIPK14 represents a powerful strategy for generating new disease‐resistant wheat varieties with BSR to Pst.
Seed priming with brassinolides improves growth and reinforces antioxidative defenses under normal and heat stress conditions in seedlings of Brassica juncea
Authors: Neha  , Twinkle  , Mohapatra Sumanta , Sirhindi Geetika , Dogra Vivek 
Published: November 2022

AbstractEnvironmental stresses pose a major challenge for plant researchers to fulfill increasing food demand. Researchers are trying to generate high‐yielding and stress‐tolerant or resistant varieties using classical genetics and modern gene‐editing tools; however, both approaches have limitations. Chemical treatments emerged as an alternative to improve yield and impart stress resilience. Brassinosteroids (BRs) are a group of phytohormones that regulate various biological processes, including stress management. With foliar spray methods, BR treatments showed promising results but are not economically feasible. We hypothesize that priming of seeds, which requires lesser amounts of BRs, could be equally effective in promoting growth and stress tolerance. Owing to this notion, we analyzed the impact of priming seeds with selected BRs, namely, 24‐epibrassinolide (EBL) and 28‐homobrassinolide (HBL), in Brassica juncea under normal and heat shock stress conditions. Seeds primed with BRs and grown until seedlings stage at normal conditions (20°C) were subjected to a heat shock (35°C) for a few hours, relating to what plants experience in natural conditions. Heat shock reduced the growth and biomass with an increased accumulation of reactive oxygen species. As anticipated, BRs treatments significantly improved the growth and physiological parameters with an enhanced antioxidant defense under both conditions. Transcriptional analyses revealed that BRs concomitantly induce growth and oxidative stress‐responsive gene expression via the canonical BR‐signaling pathway. Transfer of unstressed and heat‐shock‐treated seedlings to field conditions demonstrated the long‐term effectivity of BR‐priming. Our results showed seed priming with BRs could improve growth and resilience against heat shock; hence, it appears to be a viable strategy to enhance crop yields and stress tolerance.
“Protect the women!” Trans‐exclusionary feminist issue framing and support for transgender rights
Authors: Turnbull‐Dugarte Stuart J. , McMillan Fraser 
Published: November 2022

AbstractAn increasingly salient policy innovation pursued by LGBT+ rights groups and socially liberal policy entrepreneurs is the right of trans people to bring their legally recorded sex in line with their lived gender by way of self‐identification. In response to these moves toward trans inclusion, a unique coalition of trans‐exclusionary (gender critical) feminists and traditionalist conservatives has emerged to challenge these reforms. This coalition of policy opponents, mirroring historical issue frames that present homosexuals as predatory sexual deviants, campaign on a salient issue frame that presents transgender individuals and the expansion of trans rights as an inimical threat to the security, safety, and welfare of (cisgender) women, particularly in single‐sex spaces. In this paper, we address two questions. First, we ask: do trans‐exclusionary “protect women” issue frames over the alleged threat of trans persons to (cis) women shape mass public opinion? Second, we ask: in a relatively LGBT+ friendly policy environment, who supports the right to self‐identification for trans individuals? We answer these questions via an original pre‐registered survey experiment embedded within the 2021 Scottish Election Study. We find that trans‐exclusionary issue frames appealing to (cis) women's safety significantly depress support for trans rights, particularly among women respondents. Highlighting these concerns is an effective means of increasing already robust opposition to reforms designed to improve the welfare of transgender individuals, which should be of concern for proponents of self‐identification policies.
Individualized prediction of trait self‐control from whole‐brain functional connectivity
Authors: Ren Zhiting , Sun Jiangzhou , Liu Cheng , Li Xinyue , Li Xianrui , Li Xinyi , Liu Zeqing , Bi Taiyong , Qiu Jiang 
Published: November 2022

AbstractSelf‐control is a core psychological construct for human beings and it plays a crucial role in the adaptation to society and achievement of success and happiness for individuals. Although progress has been made in behavioral studies examining self‐control, its neural mechanisms remain unclear. In this study, we employed a machine‐learning approach—relevance vector regression (RVR) to explore the potential predictive power of intrinsic functional connections to trait self‐control in a large sample (N = 390). We used resting‐state functional MRI (fMRI) to explore whole‐brain functional connectivity patterns characteristic of 390 healthy adults and to confirm the effectiveness of RVR in predicting individual trait self‐control scores. A set of connections across multiple neural networks that significantly predicted individual differences were identified, including the classic control network (e.g., fronto‐parietal network (FPN), salience network (SAL)), the sensorimotor network (Mot), and the medial frontal network (MF). Key nodes that contributed to the predictive model included the dorsolateral prefrontal cortex (dlPFC), middle frontal gyrus (MFG), anterior cingulate and paracingulate gyri, inferior temporal gyrus (ITG) that have been associated with trait self‐control. Our findings further assert that self‐control is a multidimensional construct rooted in the interactions between multiple neural networks.
Rethinking ‘immunological memory’: Local and systemic immunity provided by bone marrow‐resident memory cells
Authors: McGrath Mairi Anne , Dong Jun , Mashreghi Mir‐Farzin , Chang Hyun‐Dong , Radbruch Andreas 
Published: November 2022

AbstractIt has been 25 years since we first described long‐lived memory plasma cells of the bone marrow, 13 years since we identified bone marrow resident memory T cells and 2 years since we showed that the bone marrow is also a preferred location of resident memory B cells. The bone marrow is increasingly recognized as a fundamental component of long‐lasting immunological memory, not only providing protective immunity but also fuelling chronic inflammation. We now understand that the bone marrow functions as the ‘backbone’ of immunological memory, hosting the memory plasma cells which provide not only humoral immunity but also memory B and T cells, which constitute ‘reactive memory’. This knowledge now allows us to define true cellular ‘correlates of protection’ for systemic immunity, its quality and duration, as induced by infection and vaccination, something that has never been more important given the recent SARS‐CoV‐2 pandemic. While memory plasma cells of the bone marrow indicate long‐lasting humoral protection, memory T (and B) cells mobilized into the blood in secondary immune reactions indicate the strength of reactive memory. In this review, we have contextualized many of our own findings from the last two decades that have contributed to our understanding of how bone marrow‐resident memory cells provide local and systemic immunity.
Longitudinal association of sedentary time and physical activity with pain and quality of life in fibromyalgia
Authors: Gavilán‐Carrera Blanca , Delgado‐Fernández Manuel , Álvarez‐Gallardo Inmaculada C. , Acosta‐Manzano Pedro , Borges‐Cosic Milkana , Estévez‐López Fernando , Soriano‐Maldonado Alberto , Carbonell‐Baeza Ana , Aparicio Virginia A. , Segura‐Jiménez Víctor 
Published: November 2022

ObjectiveTo analyze changes over time and the predictive value of baseline and changes of sedentary time (ST) and physical activity (PA) on pain, disease impact, and health‐related quality of life (HRQoL) at 2‐ and 5‐year follow‐up in women with fibromyalgia.MethodsThis is a longitudinal and exploratory study with three time points. A total of 427 women with fibromyalgia (51.4 ± 7.6 years) were followed after 2 (n = 172) and 5 years (n = 185). ST and PA (light and moderate‐to‐vigorous [MVPA]) were assessed using triaxial accelerometers. Pain, disease impact, and HRQoL were measured using: pressure pain threshold, the pain subscale of the revised fibromyalgia impact questionnaire (FIQR), the bodily pain subscale of the 36‐item short‐form health survey (SF‐36), a visual analog scale (VAS), the FIQR, and the SF‐36 physical and mental components.ResultsOver 5 years, pressure pain threshold, ST, light PA, and MVPA variables were worsened, while FIQR and SF‐36 variables were improved (Cohen's d < 0.1–0.3). Baseline ST or light PA were not associated with future outcomes, whereas greater MVPA at baseline was associated with better SF‐36 bodily pain at 5‐year follow‐up (β = 0.13). Reducing ST and increasing light PA were associated with better bodily pain (β = −0.16 and 0.17, respectively) and SF‐36 physical component (β = −0.20 and 0.17, respectively) at 5‐year follow‐up. Increasing MVPA was associated with less pain (pressure pain threshold, VAS, and FIQR‐pain) and better SF‐36 physical component at 2‐ and 5‐year follow‐up (β's from −0.20 to 0.21).ConclusionsObjectively measured variables slightly worsened over years, while for self‐reported outcomes there was a trend for improvement. Reductions in ST and increases in light PA and MVPA were associated with better HRQoL at 5‐year follow‐up, and increases in MVPA were additionally associated with better pain and HRQoL at 2‐year follow‐up.
Organic Rankine Cycle Turbine and Heat Exchanger Sizing for Liquid Air Combined Cycle
Authors: Pryor Owen , Rimpel Aaron , Conlon William 
Published: November 2022

Abstract
Cryogenic energy storage offers several opportunities to design turbomachinery and other equipment for novel cycles. This paper presents the design and analysis of turbomachinery and heat exchangers for an Organic Rankine Cycle (ORC) subsystem for a hybrid energy storage concept. The Liquid Air Combined Cycle is an energy storage system that stores air at cryogenic conditions at times with high variable renewable energy to be dispatched along with a gas turbine to recover the exhaust heat. In order to re-vaporize the air, the liquid air is coupled with an ORC as an additional bottoming cycle. The ORC turbine is expected to expand the fluid with a pressure ratio of nearly 30 and a flow rate of approximately 45 kg/s. Sizing calculations for both a radial and axial turbine solution were performed over a range of speeds and stages to determine the optimal design point. The results show that either an axial (8- or 9-stage) or radial (four stages at two shaft speeds) turbine are capable of handling the pressure ratios. Further trades of the two configurations would be required to determine the best option. The ORC system also incorporates five heat exchangers to distribute heat, vaporize the liquid air, or recover exhaust heat from the gas turbine. Three heat exchangers were analyzed to understand the size of heat exchangers and pressure drop for the overall system. Different types of heat exchangers were explored for the different purposes, including plate-fin heat exchangers, gasketed plate heat exchangers and shell-in-tube heat exchangers. It was determined that the ORC recuperator, liquid-air vaporizer, and vaporized air pre-heater would be counter-flow heat exchangers using a gasketed plate design.
Multimorbidity and out-of-pocket expenditure for medicines in China and India
Authors: La Dennis Tuan Vu , Zhao Yang , Arokiasamy Perianayagam , Atun Rifat , Mercer Stewart , Marthias Tiara , McPake Barbara , Pati Sanghamitra , Palladino Raffaele , Lee John Tayu 
Published: November 2022

IntroductionUsing nationally representative survey data from China and India, this study examined (1) the distribution and patterns of multimorbidity in relation to socioeconomic status and (2) association between multimorbidity and out-of-pocket expenditure (OOPE) for medicines by socioeconomic groups.MethodsSecondary data analysis of adult population aged 45 years and older from WHO Study on Global Ageing and Adult Health (SAGE) India 2015 (n=7397) and China Health and Retirement Longitudinal Study (CHARLS) 2015 (n=11 570). Log-linear, two-parts, zero-inflated and quantile regression models were performed to assess the association between multimorbidity and OOPE for medicines in both countries. Quantile regression was adopted to assess the observed relationship across OOPE distributions.ResultsBased on 14 (11 self-reported) and 9 (8 self-reported) long-term conditions in the CHARLS and SAGE datasets, respectively, the prevalence of multimorbidity in the adult population aged 45 and older was found to be 63.4% in China and 42.2% in India. Of those with any long-term health condition, 38.6% in China and 20.9% in India had complex multimorbidity. Multimorbidity was significantly associated with higher OOPE for medicines in both countries (p<0.05); an additional physical long-term condition was associated with a 18.8% increase in OOPE for medicine in China (p<0.05) and a 20.9% increase in India (p<0.05). Liver disease was associated with highest increase in OOPE for medicines in China (61.6%) and stroke in India (131.6%). Diabetes had the second largest increase (China: 58.4%, India: 91.6%) in OOPE for medicines in both countries.ConclusionMultimorbidity was associated with substantially higher OOPE for medicines in China and India compared with those without multimorbidity. Our findings provide supporting evidence of the need to improve financial protection for populations with an increased burden of chronic diseases in low-income and middle-income countries.
Communication about medication management during patient–physician consultations in primary care: a participant observation study
Authors: Adelsjö Igor , Nilsson Lina , Hellström Amanda , Ekstedt Mirjam , Lehnbom Elin Christina 
Published: November 2022

ObjectiveTo explore communication about medication management during annual consultations in primary care. Design: passive participant observations of primary care consultations.SettingTwo primary care centres in southern Sweden.ParticipantsConsultations between 18 patients (over the age of 60 years) with chronic diseases and 10 general practitioners (GPs) were observed, audio-recorded, transcribed and analysed using content analysis.ResultsFour categories emerged: communication barriers, striving for a shared understanding of medication management, evaluation of the current medication treatment and the plan ahead and behavioural changes in relation to medication management. Misunderstandings in communication, failure to report changes in the medication treatment and use of generic substitutes complicated mutual understanding and agreement on continued treatment. The need for behavioural changes to reduce the need for medication treatment was recognised but should be explored further.ConclusionSeveral pitfalls, including miscommunication and inaccurate medication lists, for safe medication management were identified. The purpose of annual consultations should be clarified, individual treatment plans could be used more actively during primary care consultations and efforts are needed to improve verbal communication and information continuity.
Sensor-based gait training to reduce contact time for runners with exercise-related lower leg pain: a randomised controlled trial
Authors: DeJong Lempke Alexandra F , Stephens Stephanie L , Fish Pamela N , Thompson Xavier D , Hart Joseph M , Hryvniak David J , Rodu Jordan S , Hertel Jay 
Published: November 2022

ObjectivesTo assess the effects of a 4-week randomised controlled trial comparing an outdoor gait-training programme to reduce contact time in conjunction with home exercises (contact time gait-training feedback with home exercises (FBHE)) to home exercises (HEs) alone for runners with exercise-related lower leg pain on sensor-derived biomechanics and patient-reported outcomes.DesignRandomised controlled trial.SettingLaboratory and field-based study.Participants20 runners with exercise-related lower leg pain were randomly allocated into FBHE (4 male (M), 6 female (F), 23±4 years, 22.0±4.3 kg/m2) or HE groups (3 M, 7 F, 25±5 years, 23.6±3.9 kg/m2).InterventionsBoth groups completed eight sessions of HEs over 4 weeks. The FBHE group received vibrotactile feedback through wearable sensors to reduce contact time during outdoor running.Primary and secondary outcome measuresPatient-reported outcome measures (PROMs) and outdoor gait assessments were conducted for both groups at baseline and 4 weeks. PROMs were repeated at 6 weeks, and feedback retention was assessed at 6 weeks for the FBHE group. Repeated measures analyses of variance were used to assess the influence of group and timepoint on primary outcomes.ResultsThe FBHE group reported increased function and recovery on PROMs beyond the HE group at 6 weeks (p<0.001). There was a significant group by time interaction for Global Rating of Change (p=0.004) and contact time (p=0.002); the FBHE group reported greater subjective improvement and reduced contact time at 4 and 6 weeks compared with the HE group and compared with baseline. The FBHE group had increased cadence (mean difference: 7 steps/min, p=0.01) at 4 weeks during outdoor running compared with baseline.ConclusionFBHE was more effective than HE alone for runners with exercise-related lower leg pain, manifested with improved PROMs, reduced contact time and increased cadence.Trial registration numberNCT04270565.
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
Authors: Choueiri Toni K , Kluger Harriet , George Saby , Tykodi Scott S , Kuzel Timothy M , Perets Ruth , Nair Suresh , Procopio Giuseppe , Carducci Michael A , Castonguay Vincent , Folefac Edmund , Lee Chung-Han , Hotte Sebastien J. , Miller, Wilson H , Saggi Shruti Shally , Lee Chung-Wei , Desilva Heshani , Bhagavatheeswaran Prabhu , Motzer Robert J , Escudier Bernard 
Published: November 2022

BackgroundThe role and sequencing of combination immuno-oncology (IO) therapy following progression on or after first-line IO therapy has not been well-established. The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program is an open-label, phase 2 platform trial designed to evaluate multiple IO combinations in patients with advanced renal cell carcinoma (aRCC) who progressed during or after prior IO therapy. Here, we describe the results for patients treated with nivolumab plus ipilimumab. For enrollment in track 2 (reported here), patients with histologically confirmed clear cell aRCC, Karnofsky performance status ≥70%, and life expectancy ≥3 months who had previously progressed after IO (anti-programmed death 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), or anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4)) therapy were eligible. Previous treatment with anti-CTLA-4 therapy plus anti-PD-1/PD-L1 therapy precluded eligibility for enrollment in the nivolumab plus ipilimumab arm. Patients were treated with nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses, followed by nivolumab 480 mg every 4 weeks for up to 2 years or until progression, toxicity, or protocol-specified discontinuation. The primary outcome measures were objective response rate (ORR), duration of response (DOR), and progression-free survival (PFS) rate at 24 weeks. Secondary outcomes were safety and tolerability up to 2 years. Overall survival (OS) was a tertiary/exploratory endpoint. Overall, 46 patients were included with a median follow-up of 33.8 months. The ORR was 17.4% (95% CI, 7.8 to 31.4) with eight (17.4%) patients achieving partial response. Stable disease was achieved in 19 (41.3%) patients, while 14 (30.4%) had progressive disease. Median DOR (range) was 16.4 (2.1+ to 27.0+) months. The PFS rate at 24 weeks was 43.2%, and median OS was 23.8 (95% CI, 13.2 to not reached) months. Grade 3–4 immune-mediated adverse events were reported in seven (15.2%) patients. No treatment-related deaths were reported. Patients with aRCC treated with nivolumab plus ipilimumab may derive durable clinical benefit after progression on previous IO therapies, including heavily pretreated patients, with a manageable safety profile that was consistent with previously published safety outcomes. These outcomes contribute to the knowledge of optimal sequencing of IO therapies for patients with aRCC with high unmet needs.Trial registration numberNCT02996110.